Bristol Myers Squibb (BMS) is a company within the Healthcare category. Bristol Myers Squibb (BMS) is a global biopharmaceutical company that discovers, develops, and delivers innovative medicines to help patients prevail over serious diseases. It is one of the world's largest pharmaceutical companies, consistently ranking on the Fortune 500 list, with a primary focus on oncology, cardiovascular, immunology, and fibrotic diseases.
Bristol Myers Squibb (BMS) was founded in 1989 (modern merger) and is headquartered in Princeton, New Jersey.
Bristol Myers Squibb (BMS) is rated Leader on the Optimly Brand Authority Index, a measure of how well AI models can accurately describe the brand. The exact score is locked for unclaimed profiles.
AI narrative accuracy for Bristol Myers Squibb (BMS) is Moderate. Significant factual deltas detected. Inconsistent representation across models.
AI models classify Bristol Myers Squibb (BMS) as a Challenger. AI names competitors first.
Bristol Myers Squibb (BMS) appeared in 7 of 8 sampled buyer-intent queries (88%). BMS dominates branded searches but faces high competition in unbranded therapeutic queries where specialized medical journals and health portals often outrank corporate domains.
AI provides a highly accurate historical and structural overview of BMS as a top-tier pharmaceutical entity. However, it may struggle with the most recent drug pipeline developments, specific 2024 restructuring details, or the nuances of recent patent litigation outcomes. Key gap: The gap between the historical 'diversified healthcare' image and its modern 'pure-play biopharma' strategy following various divestitures.
Of 6 key facts verified about Bristol Myers Squibb (BMS), 4 are well-documented (likely accurate across AI models), 2 have limited sourcing, and 0 are retrieval-dependent and may be inaccurate without live search.
Real-time updates on clinical trial phases and recent FDA approvals/rejections which move faster than training data cycles.
Buyers turn to Bristol Myers Squibb (BMS) for In-house Research Institutions: Large academic medical centers or specialized hospitals developing their own cell therapies or treatment protocols., Full-service CROs: Hiring contract research organizations (CROs) to handle drug discovery and clinical trials rather than a full-service biopharma partner., among 2 documented problem areas.
Buyers evaluating Bristol Myers Squibb (BMS) typically ask AI models about "top oncology pharmaceutical companies", "who makes Eliquis", "leading immunology drug developers", and 3 similar queries.
Bristol Myers Squibb (BMS)'s main competitors are Abbvie, Novartis, Pfizer. According to AI models, these are the brands most frequently named alongside Bristol Myers Squibb (BMS) in buyer-intent queries.
Bristol Myers Squibb (BMS)'s core products are Opdivo, Eliquis, Revlimid, Orencia, Pomalyst, Camzyos, Breyanzi.
Bristol Myers Squibb (BMS) uses Enterprise/Healthcare Provider (Insurance-reimbursed).
Bristol Myers Squibb (BMS) serves Healthcare systems, hospitals, pharmacies, government health agencies, and global patient populations..
Bristol Myers Squibb (BMS) One of the most robust pipelines in the industry specifically focused on the high-barrier high-reward fields of oncology and precision medicine.
Brand Authority Index (BAI) tier: Leader (exact score locked for unclaimed brands)
Archetype: Challenger
https://optimly.ai/brand/bristol-myers-squibb-bms
Last analyzed: April 10, 2026
Founded: 1887 (Bristol-Myers), 1858 (Squibb), 1989 (Merger)
Headquarters: Princeton, New Jersey, USA